Head-to-head · Cost-Efficiency Index
CoreAge Rx vs bmiMD
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
CoreAge Rx
Anyone optimizing for real value — a transparent flat price you can model for a full year, nationwide, without a bait-and-switch.
Visit CoreAge RxbmiMD
Price-driven shoppers who want both molecules cheap and nationwide, with a real month-to-month option if they don't want to prepay a year.
Visit bmiMDThe verdict
CoreAge Rx takes it, leading the Cost-Efficiency Index 94 to 82. Best value in the ranking: both molecules at one flat, all-50 price with no teaser step-ups — the lowest true cost of ownership, not the lowest teaser. bmiMD still earns a B− — Price-driven shoppers who want both molecules cheap and nationwide, with a real month-to-month option if they don't want to prepay a year.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | CoreAge Rx | bmiMD |
|---|---|---|
| Cost-Efficiency Index | 94/100 | 82/100 |
| Semaglutide / mo | $99/mo | $129/mo (true month-to-month; $99/mo requires 12-mo prepay) |
| Tirzepatide / mo | $149/mo | $179/mo (true month-to-month; $139/mo requires 12-mo prepay) |
| Semaglutide / yr (modeled) | $1,188 | $1,548 |
| Tirzepatide / yr (modeled) | $1,788 | $2,148 |
| Coverage | All 50 states | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank here | #1 | #24 |
CoreAge Rx
94/100Where the value is
- Flat all-in monthly price — no intro rate that silently triples after month one, so the modeled annual cost is the real cost
- Both compounded semaglutide and tirzepatide on one account at published prices
- Available in all 50 states — no coverage gamble
The tradeoffs
- Not the rock-bottom sticker price — 30 of the 371 priced semaglutide programs we track list a cheaper figure, though most attach a term or a step-up that CoreAge does not
- No FDA-approved brand-name option (compounded only)
bmiMD
82/100Where the value is
- Low prices on both molecules even month-to-month — $129 semaglutide / $179 tirzepatide, with no dose-based escalation
- A genuine no-commitment month-to-month option exists alongside the cheaper prepay tiers, unlike sites that gate pricing entirely behind a term
- Nationwide all-50 access with both molecules disclosed
The tradeoffs
- The advertised $99/$139 headline requires a full 12-month prepay ($1,188/$1,668 paid upfront) — the true month-to-month rate is 29-30% higher
- Compounded only — no oral or brand option
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.